Benefits of valoctocogene roxaparvovec persist in hemophilia A
For patients with hemophilia A, factor VIII activity and bleeding reduction persist at two years after gene transfer with valoctocogene roxaparvovec, which delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated ...
Mar 3, 2023
0
26